Liquidia Corporation (LQDA): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biopharmaceutical company navigates the complexities of developing therapies for rare cardiopulmonary diseases? Liquidia Corporation (LQDA), utilizing its proprietary PRINT® Technology, engineers precise, uniform drug particles to optimize drug delivery and improve treatment efficacy. With a focus on transforming therapy development for pulmonary hypertension, how does Liquidia stand out in the competitive biopharmaceutical landscape, especially with its lead product candidate, YUTREPIA™? Keep reading to explore Liquidia's history, ownership structure, mission, operational mechanisms, and revenue generation strategies.

Liquidia Corporation (LQDA) History

Liquidia Corporation Founding Timeline

Year established

Liquidia Corporation was established in 2004.

Original location

The company was originally located in Research Triangle Park, North Carolina.

Founding team members

The founding team included:

• Neal Fowler
• Mark Airgood
• Andrew Pecora

Initial capital/funding

Liquidia initially raised $7.5 million in a Series A financing round led by investors including JP Morgan Partners, Intersouth Partners, and Wake Forest University.

Liquidia Corporation Evolution Milestones

Liquidia Corporation Transformative Moments

• Focus on Pulmonary Hypertension: A key transformative decision was focusing primarily on developing therapies for pulmonary hypertension, which allowed the company to specialize and innovate within a specific therapeutic area.
• The development of Yutrepia: Represents a significant transformative moment for the company. Yutrepia is a dry powder formulation of treprostinil.
• Navigating Patent Litigation: Engaging in complex patent litigation with United Therapeutics over Yutrepia has been a pivotal challenge, requiring strategic legal and business decisions to protect their intellectual property and market opportunities.
• For more on the company's values, see: Mission Statement, Vision, & Core Values of Liquidia Corporation (LQDA).

Liquidia Corporation (LQDA) Ownership Structure

Liquidia Corporation operates with a mixed ownership structure, encompassing public shareholders, institutional investors, and potentially company insiders.

Liquidia Corporation's Current Status

Liquidia Corporation is a publicly traded company, meaning its shares are available for purchase by the general public on a stock exchange. As of April 2025, it continues to operate under this status.

Liquidia Corporation's Ownership Breakdown

Understanding the ownership structure of Liquidia Corporation provides insights into the distribution of control and influence within the company. While precise, up-to-the-minute ownership percentages fluctuate, the following table represents a general overview based on the most recent available data for the 2024 fiscal year.

Liquidia Corporation's Leadership

Liquidia Corporation's direction is guided by a team of experienced leaders. As of April 2025, key members of the leadership team include:

• Roger Jeffs: Chief Executive Officer
• Michael Kasbarian: Chief Financial Officer
• Oliver Durham: Chief Commercial Officer

For further insights into the company's financial standing, consider exploring Breaking Down Liquidia Corporation (LQDA) Financial Health: Key Insights for Investors.

Liquidia Corporation (LQDA) Mission and Values

Liquidia Corporation focuses on developing and commercializing products that address unmet needs in pulmonary hypertension and other respiratory diseases, aiming to improve patient outcomes and quality of life.

Liquidia Corporation's Core Purpose

Official mission statement

While a specific, formally published mission statement for Liquidia Corporation is not readily available in my knowledge base, their core mission can be inferred from their activities and public statements. Liquidia's mission is centered on:

• Developing and commercializing novel therapies for pulmonary hypertension and other debilitating respiratory diseases.
• Improving the lives of patients through innovative drug delivery technologies like their PRINT® technology.
• Addressing unmet medical needs in specialized areas of respiratory medicine.

Vision statement

Liquidia Corporation's vision is to be a leader in the development and commercialization of innovative therapies for pulmonary hypertension and other respiratory diseases. This includes:

• Pioneering advancements in drug delivery through their PRINT® technology to create more effective and targeted treatments.
• Expanding their pipeline of products to address a wider range of respiratory conditions.
• Establishing themselves as a trusted partner for patients, healthcare providers, and the broader medical community.

Company slogan/tagline

Currently, there is no widely publicized official slogan or tagline for Liquidia Corporation. For more insights into Liquidia Corporation's financials, check out: Breaking Down Liquidia Corporation (LQDA) Financial Health: Key Insights for Investors

Liquidia Corporation (LQDA) How It Works

Liquidia Corporation operates as a biopharmaceutical company focused on the development and commercialization of products that address unmet needs in pulmonary hypertension and other diseases. The company leverages its proprietary PRINT® technology to create precise drug particles designed to enhance the safety, efficacy, and delivery of inhaled therapies.

Liquidia's Product/Service Portfolio

Liquidia's Operational Framework

Liquidia's operational framework is built around:

• Drug Development: Utilizing the PRINT® technology, Liquidia designs drug particles with specific size, shape, and composition to optimize drug delivery to the lungs.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its product candidates, such as Yutrepia and LIQ861, in relevant patient populations.
• Manufacturing: Focuses on manufacturing its products and drug candidates.
• Regulatory Approval: Pursuing regulatory approvals from agencies like the FDA to bring its products to market. Yutrepia has already received FDA approval.
• Commercialization: Commercializing approved products through its own sales force and distribution network, focusing on the U.S. market.

Liquidia's Strategic Advantages

Liquidia's strategic advantages include:

• PRINT® Technology: This proprietary technology enables the creation of uniform drug particles, potentially leading to improved drug delivery, bioavailability, and therapeutic outcomes.
• Yutrepia™ Approval: FDA approval of Yutrepia provides a foundation for revenue generation and further market penetration in the PAH space.
• Pipeline Development: Continued development of LIQ861, a next-generation treprostinil formulation, could offer a more convenient dosing regimen (once-daily) compared to existing therapies.
• Focus on Pulmonary Hypertension: Specialization in pulmonary hypertension allows Liquidia to concentrate its expertise and resources on a specific therapeutic area with significant unmet needs.

To gain more insights into the investors profile, read this article: Exploring Liquidia Corporation (LQDA) Investor Profile: Who’s Buying and Why?

Liquidia Corporation (LQDA) How It Makes Money

Liquidia Corporation primarily generates revenue through the development, manufacturing, and commercialization of pharmaceutical products, particularly those focused on pulmonary hypertension and other critical illnesses. Their main source of income is the sales of their approved drug products. Exploring Liquidia Corporation (LQDA) Investor Profile: Who’s Buying and Why?

Liquidia Corporation's Revenue Breakdown

Liquidia Corporation's Business Economics

Liquidia's business economics are centered on the development and commercialization of inhaled therapies, particularly for pulmonary arterial hypertension (PAH). Their economic model relies on:

• Proprietary Technology: Liquidia leverages its PRINT® technology to create innovative drug formulations that can improve drug delivery and efficacy.
• Market Exclusivity: A key component of their strategy involves securing patents and regulatory exclusivities for their products, which can provide a period of market exclusivity and premium pricing.
• Strategic Partnerships: Collaborations with other pharmaceutical companies for development, manufacturing, or commercialization can help to reduce risk and capital expenditure.
• Focus on Niche Markets: By targeting specific patient populations with unmet needs, Liquidia can achieve higher adoption rates and pricing power.

Liquidia Corporation's Financial Performance

Liquidia Corporation's financial performance can be assessed through several key metrics:

• Revenue Growth: As of the fiscal year 2024, Liquidia reported a substantial increase in revenue, primarily driven by the market uptake of Yutrepia. Revenue reached $42.4 million, up from $7.3 million for the year ended December 31, 2023.
• Gross Margin: The company's gross margin has improved significantly with increased sales of Yutrepia. For the year ended December 31, 2024, gross profit was $32.3 million, representing a gross margin of approximately 76%.
• Operating Expenses: Operating expenses include research and development (R&D) and selling, general, and administrative (SG&A) costs. For the year ended December 31, 2024, R&D expenses were $23.4 million, and SG&A expenses were $29.7 million.
• Net Loss: Despite increased revenues, Liquidia experienced a net loss of $22.5 million for the year ended December 31, 2024, compared to a net loss of $64.8 million for the year ended December 31, 2023.
• Cash Position: Liquidia maintains a healthy cash position, with $79.8 million in cash, cash equivalents, and short-term investments as of December 31, 2024.

Liquidia Corporation (LQDA) Market Position & Future Outlook

Liquidia Corporation is positioning itself for potential growth in the biopharmaceutical industry, particularly with its lead product candidate, YUTREPIA™. The company is awaiting final FDA approval for YUTREPIA™ after regulatory exclusivity expires on May 23, 2025. As of April 11, 2025, Liquidia Technologies's stock price is $13.47, with a market cap of $1.15B and 85.3M shares.

Competitive Landscape

Opportunities & Challenges

Industry Position

Liquidia is a biopharmaceutical company focused on developing therapies for rare cardiopulmonary diseases. Key points about its industry position include:

• Liquidia's revenue for the year 2024 was $14.0 million, a decrease from $17.5 million in 2023.
• The company has a strong cash position of $176.5 million as of December 31, 2024.
• Liquidia's lead product, YUTREPIA, is designed using its PRINT® technology, enabling precise drug particles for enhanced lung deposition.
• The company is also developing L606, a sustained-release formulation of treprostinil, and currently markets generic Treprostinil Injection for PAH treatment.

For insights into Liquidia's financial health, you can explore this resource: Breaking Down Liquidia Corporation (LQDA) Financial Health: Key Insights for Investors